AstraZeneca has announced a $2.5 billion investment in a research and development hub in Beijing, underscoring its commitment to China, its second-largest market. This initiative includes two licensing deals with Chinese firms and aims to leverage Beijing's advanced life sciences and AI capabilities. Chief executive Pascal Soriot highlights the extensive collaboration opportunities and access to talent in China.